ESMO 2025 and new therapies in breast cancer: does society always benefit?

Area of Science:

• Oncology
• Clinical Trials
• Translational Research

Background:

• Breast cancer treatment continues to evolve with new therapeutic strategies.
• Identifying high-risk patient populations is crucial for optimizing adjuvant and metastatic care.
• Biomarker-driven approaches are increasingly important in personalized oncology.

Purpose of the Study:

• To summarize pivotal data presented at the ESMO 2025 Congress impacting breast cancer clinical decision-making.
• To highlight advancements in adjuvant and metastatic breast cancer treatment paradigms.
• To discuss the societal implications of new breast cancer therapies and diagnostic guidelines.

Main Methods:

• Review of key presentations and data from the ESMO 2025 Congress.
• Analysis of clinical trial outcomes for novel therapeutics and established agents.
• Synthesis of updated guideline recommendations and emerging trends in breast cancer management.

Main Results:

• First demonstration of overall survival benefit for adjuvant CDK4/6 inhibitors in high-risk HR+/HER2- early breast cancer.
• Trastuzumab deruxtecan (T-DXd) established as a standard of care for high-risk HER2+ disease.
• Novel antibody-drug conjugates (ADCs) show promise in redefining first-line therapy for metastatic triple-negative breast cancer (TNBC).
• Updated guidelines recommend broader next-generation sequencing (NGS) profiling for specific genetic alterations (PALB2, AKT1, PTEN).
• Emphasis on biomarker-driven de-escalation, strategic treatment sequencing, and managing endocrine resistance.

Conclusions:

• ESMO 2025 presented practice-defining data that significantly reshapes breast cancer treatment strategies.
• The integration of novel agents and expanded molecular profiling offers improved outcomes for various breast cancer subtypes.
• Balancing therapeutic benefits with cost, equity, and biomarker validation is essential for responsible implementation.